← Back to Search

Other

MRX-2843 for Advanced Refractory Cancer

Phase 1
Waitlist Available
Led By Donald Harvey
Research Sponsored by Meryx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Nonsterilized males who are sexually active with a female of childbearing potential must agree to use an acceptable method of effective contraception
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 14 days after last dose of study treatment (up to approximately 12 months)
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and works well against cancer that has come back or does not respond to other treatments.

Who is the study for?
Adults with advanced solid tumors that have relapsed or spread, who've tried at least one treatment without success. They must be over 18, able to take oral meds, and not pregnant or breastfeeding. Participants need normal organ function tests and agree to use effective contraception during the trial.Check my eligibility
What is being tested?
The study is testing MRX-2843's safety and how it moves through the body (pharmacokinetics) in people with stubborn cancers that haven't responded well to other treatments. It's an early-stage trial where everyone gets MRX-2843.See study design
What are the potential side effects?
Specific side effects of MRX-2843 aren't listed but may include typical reactions seen with cancer drugs such as nausea, fatigue, blood count changes, liver issues, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am a man who can father children and will use birth control.
Select...
I am not pregnant, not breastfeeding, and my pregnancy test was negative.
Select...
My cancer is confirmed and can be measured or evaluated.
Select...
I've had one treatment for my advanced illness and there are no approved treatments left.
Select...
I agree to use two forms of birth control if I can have children and am sexually active.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 14 days after last dose of study treatment (up to approximately 12 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 14 days after last dose of study treatment (up to approximately 12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5
Percentage of subjects with Dose Limiting Toxicities (DLTs)
Secondary outcome measures
AUC0-inf: area under the concentration-time curve from time 0 to infinity
AUC0-t: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (t)
AUC0-τ: area under the concentration-time curve from time 0 to tau, where tau is the dosing interval
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRX-2843Experimental Treatment1 Intervention
MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD

Find a Location

Who is running the clinical trial?

Meryx, Inc.Lead Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
Donald HarveyPrincipal InvestigatorEmory University

Media Library

MRX-2843 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03510104 — Phase 1
Cancer Research Study Groups: MRX-2843
Cancer Clinical Trial 2023: MRX-2843 Highlights & Side Effects. Trial Name: NCT03510104 — Phase 1
MRX-2843 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03510104 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned MRX-2843 for public usage?

"Due to the limited clinical data that exists surrounding MRX-2843, our experts at Power assigned a score of 1 for its safety. This result is in line with expectations as this is a Phase 1 trial investigating both efficacy and safety."

Answered by AI

How many participants are actively signing up for this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical trial is actively looking for participants and has been since it was posted on May 22nd 2018. The latest update occurred on October 17th 2022 and the research team aims to enroll 45 patients in 2 different healthcare sites."

Answered by AI

Is participation in this clinical experiment available at the present moment?

"As per information on clinicaltrials.gov, enrollment for this medical research is still open. This experiment was initially posted in May 2018 and last updated in October 2022."

Answered by AI
~6 spots leftby Mar 2025